Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
As UN General Assembly Highlights Tuberculosis Fight, Will BRICS Lead on the R&D Agenda?
26 September 2018
The Center for Global Development and the Office of Health Economics are working on a new approach to drive the next generation of investment for better…
OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value
7 September 2018
OHE Lunchtime Seminar with Mariana Mazzucato on Re-imagining Health Innovation to Deliver Public Value. 28 September 2018 12:00-2:00pm.
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.
The Impact of New Medicines in the NHS: 70 Years of Innovation
14 August 2018
This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.
Opportunity Costs of New Health Care Technologies: A Research Agenda
8 August 2018
A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.
Presentations from EuHEA 2018
2 August 2018
OHE staff recently attended the European Health Economics Association (EuHEA) 2018 conference. In this blog post, we share a selection of our presentations. Establishing a Reasonable…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?
Presentations from AES and PROMs Summer 2018
24 July 2018
OHE staff recently attended AES and PROMs Summer 2018 conferences. In this blog post, we share a selection of our presentations.
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?